Full-Time
HR Manager/Senior Manager
Human Resources
Posted on 9/15/2025
Synchron
51-200 employees
Endovascular BCI for paralysis patients
Compensation Overview
$100k - $160k/yr
No H1B Sponsorship
Brooklyn, NY, USA
In Person
 People & HR (1) |
|---|
- Bachelors degree in Human Resources or related field.
- 5+ years of HR experience in a fast-paced, scaling startup environment.
- Experience supporting a company as it grew beyond 100 employees.
- Able to work onsite in our Brooklyn, NY office.
- Strong knowledge of HR processes, compliance, and labor laws.
- Hands-on experience with HRIS, payroll, and ATS.
- Exceptional organizational skills and meticulous attention to detail.
- Ability to handle sensitive information with discretion and confidentiality.
- Strong verbal and written communication skills.
- A proactive mindset: able to think long-term while executing in the short-term.
- * Partner with hiring managers to draft and post job descriptions.
- * Host hiring kickoff meetings with hiring managers and interview teams.
- * Configure interview phases and plans in our ATS (Greenhouse).
- * Conduct phone screenings, cultural interviews, and coordinate candidate feedback.
- * Manage the offer process and employment documentation.
- * Act as internal champion and “super user” of Greenhouse.
- * Serve as onboarding champion: coordinate pre-hire activities, ensure smooth day-one new hire orientation, maintain compliance posters and relevant federal and state trainings, and handle I-9/W-4/all things hiring processes.
- * Ensure new hires are set up in HRIS, payroll, and benefits systems.
- * Implement terminations, promotions, and other employee life cycle events (title/department changes, etc.), including documentation and compliance.
- * Partner with Finance/Accounting to ensure payroll changes (additions, terminations, adjustments) are accurate and timely.
- * Process payroll with appropriate checks and balances from internal stakeholders.
- * Ensure compliance with federal, state, and local labor laws (familiarity with CA and NYC labor law is a major plus).
- * Maintain HR databases and employee records in compliance with regulations.
- * Coordinate mandatory trainings (e.g., anti-harassment).
- * Design and manage the employee experience program across the full lifecycle.
- * Lead performance review cycles and coordinate career development discussions with managers.
- * Partner with leadership to run engagement surveys and implement action plans.
- * Support implementation of our career track guide and coordinate talent review sessions.
- * Work with leadership to identify and launch learning & development programs.
- * Act as in-house benefits point of contact; coordinate with brokers during renewals and support employees with benefits questions.
- * Administer benefits and payroll programs in alignment with leadership direction.
- * Provide confidential support on employee relations matters, assisting with investigations and documentation as needed.
- * Partner with admin team to plan team-building events, company celebrations, town halls, investor visits, and board meetings.
- * Champion culture and employee experience initiatives, ensuring our values scale alongside our growth.
- Familiarity with California ,New York and multi state labor laws.
- Experience managing performance review cycles, career development frameworks, and engagement surveys.
- Prior experience as the first or sole HR hire in a startup or high-growth company.
- Proven track record of implementing learning & development programs.
- Demonstrated success as a cultural champion, scaling values and engagement through rapid growth.
Synchron develops brain-computer interface (BCI) technology that enables people with severe neurological impairments to control computers and digital devices with their thoughts. Its flagship system is implanted using a minimally invasive endovascular procedure, similar to placing a stent, so no open-brain surgery is required. This makes the device accessible to more patients and reduces surgical risk. The company focuses on patients who cannot communicate or move effectively, improving autonomy and social connection by translating brain signals into device commands. Synchron differentiates itself through its endovascular implantation approach and clinical pathway, aiming to expand access and real-world use via partnerships with healthcare providers. The goal is to enhance patient independence and quality of life by safely and reliably decoding neural activity to operate digital tools.
Company Size
51-200
Company Stage
Series D
Total Funding
$334.3M
Headquarters
New York City, New York
Founded
2016
Simplify's Take
What believers are saying
- Raised $200M-$305M Series D from Double Point Ventures and Bezos Expeditions.
- Partners with Apple, Nvidia, Amazon for seamless device integration.
- Appointed Andy Rasdal as Chief of Staff and Mark Brister as VP R&D.
What critics are saying
- Neuralink implants 12 patients by January 2026, launches high-volume production.
- BISC implant packs 65,536 electrodes, one-thousandth size of Stentrode.
- Precision Neuroscience's FDA-cleared brain film targets ALS communication directly.
What makes Synchron unique
- Stentrode uses endovascular catheter delivery, avoiding open brain surgery.
- Integrates with Apple Vision Pro and Nvidia AI for iPad control.
- COMMAND study shows no serious adverse events in six patients over 12 months.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 0%2 year growth
↑ 3%The most innovative data science companies of 2026. March 24, 2026 Why Unstructured, Feedzai, Synchron, and Chalk are among Fast Company's Most Innovative Companies in data science for 2026.
The mind-machine merger: how AI is unlocking the era of brain-computer interfaces. From science fiction to clinical reality. The dream of controlling machines with thought alone has moved from science fiction to clinical reality. In 2025 and early 2026, brain-computer interfaces reached an inflection point: around 90 active BCI trials are now underway globally, and the technology is transitioning from laboratory curiosity to commercial product. What changed? Artificial intelligence. AI has become the essential ingredient that makes modern BCIs work. The human brain generates messy, noisy signals. Traditional signal processing struggled to extract meaning from this chaos. Deep learning changed the equation by finding patterns in neural data that older methods missed entirely. The Hardware revolution. Three distinct approaches are competing to become the standard for brain-computer interfaces, each with different trade-offs between invasiveness and performance. Neuralink's approach involves direct brain implantation. By January 2026, twelve patients worldwide had received Neuralink implants, and the company plans to begin high-volume production later this year. Their PRIME study has enabled individuals with quadriplegia to control computers and smartphones using thought alone. In January 2026, Neuralink launched the VOICE trial to restore speech by decoding brain signals directly into words. Synchron takes a less invasive path. Their Stentrode device is delivered through blood vessels, avoiding open brain surgery entirely. Their COMMAND study reported no device-related serious adverse events across six participants over twelve months. In January 2026, Synchron introduced an updated system integrating Nvidia AI and Apple Vision Pro, allowing a patient with ALS to control an iPad entirely by thought. The most striking development came in December 2025. Researchers from Columbia, Stanford, and the University of Pennsylvania unveiled BISC, an ultra-thin neural implant roughly as thick as a human hair. This single chip packs 65,536 electrodes into a space of about 3 cubic millimeters, making it one-thousandth the size of existing BCIs. The device slides into the narrow gap between brain and skull, creating what researchers describe as "a high-bandwidth portal for communication with AI." The AI breakthrough. Hardware advances alone would not have produced these results. The real transformation comes from how AI processes neural signals. Traditional BCIs required users to spend hours training the system to recognize their specific brain patterns. Modern AI-powered interfaces learn much faster and adapt continuously. Generative AI techniques including GANs, Variational Autoencoders, and Transformer models now address the core challenges that held BCIs back for decades: low signal-to-noise ratios, overfitting from limited training data, and the fact that brain signals change over time. Speech BCIs illustrate this progress. Earlier systems could decode a handful of words per minute with significant error rates. Current AI decoders can infer words from complex brain activity with high accuracy and low latency, a leap that makes real-time communication possible for people who cannot speak. Perhaps the most exciting development is the emergence of AI "co-pilots" for non-invasive BCIs. UCLA engineers published research in September 2025 showing that combining EEG signals with a camera-based AI system dramatically improved BCI performance. Participants, including an individual paralyzed from the waist down, completed tasks like cursor control and robotic arm manipulation that were impossible without AI assistance. The AI interprets not just what the brain signals literally encode, but what the user likely intends to do, filling in gaps and correcting errors in real time. Clinical applications taking shape. These technologies are reaching patients with real medical needs. ALS patients represent a primary focus. Neuralink patient Brad Smith used his implant to control a motorized webcam. Synchron patients have demonstrated texting and computer control through thought alone. Precision Neuroscience, founded by a Neuralink alumnus, received FDA clearance in April 2025 for their "brain film" device specifically targeting communication for ALS patients. The potential extends far beyond motor control. UCL researchers in May 2025 used AI to identify distinct electrical signatures of different brain cell types with 95% accuracy, a breakthrough that could transform understanding and treatment of epilepsy. The BISC implant's designers envision applications in treating epilepsy, spinal cord injury, stroke, and even blindness. Global competition intensifies. The race is not limited to American companies. China released a national BCI roadmap in August 2025, setting technical milestones for 2027 and aiming for a complete supply chain by 2030. Chinese researchers have completed the country's first fully implanted, wireless BCI clinical trial and achieved the first clinical application of a wireless Chinese-language BCI system for speech disability interventions. This competition will likely accelerate development. Multiple approaches, regulatory frameworks, and funding sources create an ecosystem where different solutions can emerge for different use cases. What comes next. The trajectory is clear: BCIs are becoming smaller, less invasive, more capable, and increasingly powered by AI. Several trends will shape the next few years. Integration with everyday technology is accelerating. Synchron's partnership with Apple and NVIDIA signals that BCI interfaces will connect to existing ecosystems rather than requiring entirely new platforms. This matters for adoption. A BCI that controls your existing iPhone is more useful than one that only works with specialized equipment. AI will continue improving signal interpretation. The current generation of decoders already outperforms anything available five years ago. As models improve and training data accumulates from clinical trials, accuracy and speed will keep rising. Ethical frameworks are developing alongside the technology. Questions about data privacy, access equity, and the boundaries of cognitive enhancement remain open. Researchers increasingly emphasize the need for purposeful design and multi-stakeholder collaboration to ensure these powerful tools benefit humanity broadly. The fusion of AI and neuroscience has produced something genuinely new: machines that can understand human intention directly from brain activity. For millions of people with paralysis, ALS, or other conditions that trap minds inside unresponsive bodies, this technology offers something that was impossible just a few years ago. The mind is learning to speak to machines, and machines are finally learning to listen.
Synchron raises $305m to advance brain - computer interfaces. Synchron, a medical device company that produces non-surgical brain - computer interface (BCI) devices, has secured $305 million in a Series D financing round. The funding will accelerate commercialisation of the company's first-generation Stentrode BCI platform, while advancing development of a frontier next-generation interface. The round was led by Double Point Ventures, alongside existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI and METIS. New investors include Australia's National Reconstruction Fund Corporation (NRFC), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs and IQT. The Stentrode BCI platform is billed as the world's first endovascular brain - computer interface, designed to translate brain activity into digital commands without open-brain surgery. Placed via a non-surgical catheter procedure, the Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices. It is hoped that the Stentrode BCI device will allow severely paralysed people to use digital devices with just their thoughts, enabling them to text their loved ones, control electronic appliances and perform simple household tasks for themselves. Stentrode BCIs have been placed in 10 patients with paralysis to date, across clinical trials in the US and Australia. Synchron was established in Australia in 2012 by Australian clinicians and scientists Tom Oxley, Nicholas Opie and Rahul Sharma. The company has collaborated with tech giants including Apple, NVIDIA, Amazon and Open AI, and has co-developed a Bluetooth-based iOS protocol that connects brain activity directly to Apple devices using Switch Control - with no touch, voice or eye-tracking required. With this Series D financing, Synchron will accelerate pivotal trials, prepare for commercial launch of the Stentrode BCI system, and continue hiring engineers, neuroscientists and operators to advance the next generation of brain - computer interfaces. An expanding Cognitive AI division in New York City will be training models that learn from brain data to decode thought in real time, while a new San Diego engineering hub has been established to build the world's most advanced brain interface. As it moves from clinical trials to large-scale commercial deployment, the funding will also help the company establish a commercial hub in Australia, with plans to conduct clinical trials for its technology in Australia. Ultimately, Synchron's long-term vision is to train AI directly on the cognitive functions of the brain, eventually allowing for the development of AI that understands and synthesises human cognition in real time without human input. "This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field - a next-generation, transcatheter high-channel whole-brain interface," Oxley said. Image caption: An overview of Synchron's BCI system and how it allows users with motor impairment to control their digital devices. Image credit: Synchron. Distinguished Professor Lidia Morawska's work in the study of air quality provided vital... Australian scientists Dr Carolien van de Sandt and Dr Rhys Grinter have each been awarded CSL... The $3m in funding is understood to represent the single largest non-government investment in...
The alleywatch startup daily funding report: 11/10/2025. The latest venture capital, seed, pre-seed, and angel deals for NYC startups for 11/10/2025 featuring funding details for Synchron, fomo, and much more. This page will be updated throughout the day to reflect any new fundings. Synchron - $200M Series D. Synchron, a non-surgical brain-computer interface company, has raised $200M in Series D funding led by Double Point Ventures. Founded by Nicholas Opie and Thomas Oxley in 2016, Synchron has now raised a total of $330M in reported equity funding. AlleyWatch is NYC's leading source of tech and startup news, reaching the city's most active founders, investors, and tech leaders. Advertise today fomo - $17M Series A. fomo, a cross-chain retail digital asset trading platform, has raised $17M in Series A funding led by Double Point Ventures. Founded by Paul Erlanger, Prashan Dharmasena, and Se Yong Park in 2024, fomo has now raised a total of $19M in reported equity funding.
Synchron raises US$200 million in Series D financing to advance BCI technology. Synchron has raised US$200 million via a Series D financing round, with this funding set to be used to accelerate commercialisation of the company's first-generation Stentrode brain-computer interface (BCI) platform while also advancing development of a "next-generation, transcatheter, high-channel whole-brain interface". In addition to accelerating pivotal trials and preparing for the commercial launch of its Stentrode BCI system, Synchron states in a press release that - bolstered by this Series D funding - it will continue hiring engineers, neuroscientists and operators to advance the next generation of BCIs. The round was led by Double Point Ventures alongside existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI and METIS. New investors include the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs and IQT. The financing brings Synchron's total funding to US$345 million, as reported in the company's recent release. The Stentrode BCI platform is described by Synchron as the "world's first" endovascular BCI, designed to translate brain activity into digital commands without the need for open brain surgery. Placed via a non-surgical catheter procedure, the Stentrode interfaces with the motor cortex through the blood vessels, recording and transmitting neural signals wirelessly to enable hands-free control of digital devices. Across clinical trials in the USA and Australia, Stentrode BCIs have been placed in 10 patients with paralysis to date. "We've built the first non-surgical BCI designed for everyday life for people with paralysis," said Tom Oxley, Synchron's chief executive officer (CEO) and founder. "This funding brings us closer to commercialising the Stentrode BCI platform, while accelerating development of a major breakthrough in the field - a next-generation, transcatheter, high-channel whole-brain interface." According to Synchron, an expanding cognitive artificial intelligence (AI) division in New York City, USA will be training models that learn from brain data to decode thought in real time. In parallel, its new engineering hub in San Diego, USA has been established to build "the world's most advanced brain interface". "Synchron is building the first truly scalable, minimally invasive BCI that can be deployed in everyday healthcare," commented Campbell Murray, co-founder and managing partner at Double Point Ventures. "Its fusion of neurovascular access, breakthrough device engineering and adaptive AI marks a fundamental step toward restoring digital agency to people with paralysis." "Synchron's work is expanding the frontier of what's possible between the human brain and technology," added Bob Langer, executive chairman at T Rx Capital. "This next phase brings us closer to a future where brain interfaces can potentially unlock entirely new dimensions for healthcare."